Condition
Corticobasal Degeneration (CBD)
Total Trials
9
Recruiting
4
Active
4
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 9 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 5 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed5
Recruiting4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Showing 9 of 9 trials
NCT06647641Recruiting
The CurePSP Genetics Program
NCT04363684Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT07000851Recruiting
Imaging Studies in Corticobasal Syndrome
NCT06949865Recruiting
AI-Enhanced Optimization of Acute Levodopa Challenge Test
NCT02966145CompletedPrimary
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
NCT03030586Completed
ADDIA Proof-of-Performance Clinical Study
NCT03545126Completed
Human CNS Tau Kinetics in Tauopathies
NCT02365922Completed
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
NCT02133846Phase 1Completed
Safety Study of TPI-287 to Treat CBS and PSP
Showing all 9 trials